Validation of quantitative prognostic prediction using ADV score for resection of hepatocellular carcinoma: A Korea-Japan collaborative study with 9200 patients.
hepatocellular carcinoma
microvascular invasion
recurrence
resection
tumor biology
Journal
Journal of hepato-biliary-pancreatic sciences
ISSN: 1868-6982
Titre abrégé: J Hepatobiliary Pancreat Sci
Pays: Japan
ID NLM: 101528587
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
revised:
02
02
2023
received:
05
07
2022
accepted:
10
02
2023
medline:
28
8
2023
pubmed:
23
2
2023
entrez:
22
2
2023
Statut:
ppublish
Résumé
A score derived from the concentrations of α-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) and tumor volume (TV), called ADV score, has been shown to be prognostic of hepatocellular carcinoma (HCC) recurrence following hepatic resection (HR) or liver transplantation. This multicenter, multinational validation study included 9200 patients who underwent HR from 2010 to 2017 at 10 Korean and 73 Japanese centers, and were followed up until 2020. AFP, DCP, and TV showed weak correlations (ρ ≤ .463, r ≤ .189, p < .001). Disease-free survival (DFS), overall survival (OS), and post-recurrence survival rates were dependent on 1.0 log and 2.0 log intervals of ADV scores (p < .001). Receiver operating characteristic (ROC) curve analysis showed that ADV score cutoffs of 5.0 log for DFS and OS yielded the areas under the curve ≥ .577, with both being significantly prognostic of tumor recurrence and patient mortality at 3 years. ADV score cutoffs of ADV 4.0 log and 8.0 log, derived through K-adaptive partitioning method, showed higher prognostic contrasts in DFS and OS. ROC curve analysis showed that an ADV score cutoff of 4.2 log was suggestive of microvascular invasion, with both microvascular invasion and an ADV score cutoff of 4.2 log showing similar DFS rates. This international validation study demonstrated that ADV score is an integrated surrogate biomarker for post-resection prognosis of HCC. Prognostic prediction using ADV score can provide reliable information that can assist in planning treatment of patients with different stages of HCC and guide individualized post-resection follow-up based on the relative risk of HCC recurrence.
Sections du résumé
BACKGROUND
BACKGROUND
A score derived from the concentrations of α-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) and tumor volume (TV), called ADV score, has been shown to be prognostic of hepatocellular carcinoma (HCC) recurrence following hepatic resection (HR) or liver transplantation.
METHODS
METHODS
This multicenter, multinational validation study included 9200 patients who underwent HR from 2010 to 2017 at 10 Korean and 73 Japanese centers, and were followed up until 2020.
RESULTS
RESULTS
AFP, DCP, and TV showed weak correlations (ρ ≤ .463, r ≤ .189, p < .001). Disease-free survival (DFS), overall survival (OS), and post-recurrence survival rates were dependent on 1.0 log and 2.0 log intervals of ADV scores (p < .001). Receiver operating characteristic (ROC) curve analysis showed that ADV score cutoffs of 5.0 log for DFS and OS yielded the areas under the curve ≥ .577, with both being significantly prognostic of tumor recurrence and patient mortality at 3 years. ADV score cutoffs of ADV 4.0 log and 8.0 log, derived through K-adaptive partitioning method, showed higher prognostic contrasts in DFS and OS. ROC curve analysis showed that an ADV score cutoff of 4.2 log was suggestive of microvascular invasion, with both microvascular invasion and an ADV score cutoff of 4.2 log showing similar DFS rates.
CONCLUSIONS
CONCLUSIONS
This international validation study demonstrated that ADV score is an integrated surrogate biomarker for post-resection prognosis of HCC. Prognostic prediction using ADV score can provide reliable information that can assist in planning treatment of patients with different stages of HCC and guide individualized post-resection follow-up based on the relative risk of HCC recurrence.
Substances chimiques
alpha-Fetoproteins
0
Biomarkers
0
Biomarkers, Tumor
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
993-1005Informations de copyright
© 2023 Japanese Society of Hepato-Biliary-Pancreatic Surgery.
Références
Hwang S, Lee YJ, Kim KH, Ahn CS, Moon DB, Ha TY, et al. The impact of tumor size on long-term survival outcomes after resection of solitary hepatocellular carcinoma: single-institution experience with 2558 patients. J Gastrointest Surg. 2015;19:1281-90.
Hwang S, Song GW, Lee YJ, Kim KH, Ahn CS, Moon DB, et al. Multiplication of tumor volume by two tumor markers is a post-resection prognostic predictor for solitary hepatocellular carcinoma. J Gastrointest Surg. 2016;20:1807-20.
Jung DH, Hwang S, Lee YJ, Kim KH, Song GW, Ahn CS, et al. Small hepatocellular carcinoma with low tumor marker expression benefits more from anatomical resection than tumors with aggressive biology. Ann Surg. 2019;269:511-9.
Hwang S, Joh JW, Wang HJ, Kim DG, Kim KS, Suh KS, et al. Prognostic prediction models for resection of large hepatocellular carcinoma: a Korean multicenter study. World J Surg. 2018;42:2579-91.
Park GC, Hwang S, Park YH, Choi JU, Korean Liver Cancer Study Group. Validation of prognostic impact of ADV score for resection of hepatocellular carcinoma: analysis using Korea liver cancer registry database. Ann Surg Treat Res. 2020;98:235-46.
Hwang S, Moon DB, Kim KH, Ahn CS, Song GW, Jung DH, et al. Prognostic accuracy of the ADV score following resection of hepatocellular carcinoma with portal vein tumor thrombosis. J Gastrointest Surg. 2021;25:1745-59.
Hwang S, Song GW, Ahn CS, Kim KH, Moon DB, Ha TY, et al. Quantitative prognostic prediction using ADV score for hepatocellular carcinoma following living donor liver transplantation. J Gastrointest Surg. 2021;25:2503-15.
Hwang S, Song GW, Ahn CS, Kim KH, Moon DB, Ha TY, et al. Salvage living donor liver transplantation for hepatocellular carcinoma recurrence after hepatectomy: quantitative prediction using ADV score. J Hepatobiliary Pancreat Sci. 2021;28:1000-13.
Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52-60.
Galizia MS, Töre HG, Chalian H, Yaghmai V. Evaluation of hepatocellular carcinoma size using two-dimensional and volumetric analysis: effect on liver transplantation eligibility. Acad Radiol. 2011;18:1555-60.
Botea F, Marconi M, Lutman F, Balzarini L, Roncalli M, Montorsi M, et al. Radiological estimation of size in colorectal liver metastases: is it reliable? Comparison with post-resectional measurements. Updates Surg. 2010;62:21-6.
Kim HD, Shim JH, Kim GA, Shin YM, Yu E, Lee SG, et al. Optimal methods for measuring eligibility for liver transplant in hepatocellular carcinoma patients undergoing transarterial chemoembolization. J Hepatol. 2015;62:1076-84.
Kang WH, Hwang S, Song GW, Lee YJ, Kim KH, Ahn CS, et al. Prognostic effect of transarterial chemoembolization-induced complete pathological response in patients undergoing liver resection and transplantation for hepatocellular carcinoma. Liver Transpl. 2017;23:781-90.
Liu Y, Yin G. Partitioned log-rank tests for the overall homogeneity of hazard rate functions. Lifetime Data Anal. 2017;23:400-25.
Renzulli M, Brocchi S, Cucchetti A, Mazzotti F, Mosconi C, Sportoletti C, et al. Can current preoperative imaging be used to detect microvascular invasion of hepatocellular carcinoma? Radiology. 2016;279:432-42.
Min JH, Kim YK, Lim S, Jeong WK, Choi D, Lee WJ. Prediction of microvascular invasion of hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging: impact of intra-tumoral fat detected on chemical-shift images. Eur J Radiol. 2015;84:1036-43.
Shirabe K, Toshima T, Kimura K, Yamashita Y, Ikeda T, Ikegami T, et al. New scoring system for prediction of microvascular invasion in patients with hepatocellular carcinoma. Liver Int. 2014;34:937-41.
Poté N, Cauchy F, Albuquerque M, Voitot H, Belghiti J, Castera L, et al. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. J Hepatol. 2015;62:848-54.
Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, et al. AJCC cancer staging manual. Vol 22. 8th ed. Chicago: Springer International Publishing: American Joint Commission on Cancer; 2017. p. 287-93.
Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76:681-93.
Troisi RI, Berardi G, Morise Z, Cipriani F, Ariizumi S, Sposito C, et al. Laparoscopic and open liver resection for hepatocellular carcinoma with child-Pugh B cirrhosis: multicentre propensity score-matched study. Br J Surg. 2021;108:196-204.
Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol. 2019;25:93-159.
Tanaka S, Shinkawa H, Tamori A, Takemura S, Takahashi S, Amano R, et al. Surgical outcomes for hepatocellular carcinoma detected after hepatitis C virus eradiation by direct-acting antivirals. J Surg Oncol. 2020;122:1543-52.
Ohki T, Sato K, Kondo M, Goto E, Sato T, Kondo Y, et al. Effectiveness of direct acting antiviral agents for hepatitis C virus related recurrent hepatocellular carcinoma patients who had multiple courses of recurrence. J Viral Hepat. 2021;28:1597-603.